Varlilumab
Phase 2Monoclonal antibody
Varlilumab is one of 58 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 2.
2
Indications
5
Total Trials
3
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
64 competitors in Biliary Tract Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Imfinzi
AstraZenecaPhase 3
Eloxatin
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Keytruda
Merck & Co.Phase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Abraxane
Bristol-Myers SquibbPhase 3
Herceptin
RochePhase 3
Zaniducla
Jazz PharmaceuticalsPhase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lymphoma1 trial
GBM1 trial
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Active, not recruiting·—·Phase 2·NCT03688178·43 enrolled
Glioma1 trial
Biliary Tract Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Varlilumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- NNational Cancer Institute (NCI)